Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Bryan Haugen to Thyroid Neoplasms

This is a "connection" page, showing publications Bryan Haugen has written about Thyroid Neoplasms.

 
Connection Strength
  
 
 
16.704
  
  1. Jeon MJ, Haugen BR. Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models. Endocrinol Metab (Seoul). 2022 12; 37(6):830-838.
    View in: PubMed
    Score: 0.621
  2. Mayson SE, Chan CM, Haugen BR. Tailoring the approach to radioactive iodine treatment in thyroid cancer. Endocr Relat Cancer. 2021 09 03; 28(10):T125-T140.
    View in: PubMed
    Score: 0.567
  3. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048.
    View in: PubMed
    Score: 0.474
  4. Patel NU, Lind KE, McKinney K, Clark TJ, Pokharel SS, Meier JM, Stamm ER, Garg K, Haugen B. Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer. AJNR Am J Neuroradiol. 2018 Apr; 39(4):756-761.
    View in: PubMed
    Score: 0.443
  5. French JD, Haugen BR. Thyroid cancer: CAR T cell therapy - potential in advanced thyroid cancer? Nat Rev Endocrinol. 2018 01; 14(1):10-11.
    View in: PubMed
    Score: 0.436
  6. French JD, Haugen BR. Thyroid-Specific T Cells in Patients With Differentiated Thyroid Cancer: Implications for Immune-Based Therapies? J Clin Endocrinol Metab. 2017 07 01; 102(7):2131-2132.
    View in: PubMed
    Score: 0.424
  7. Haugen BR, Sawka AM, Alexander EK, Bible KC, Caturegli P, Doherty GM, Mandel SJ, Morris JC, Nassar A, Pacini F, Schlumberger M, Schuff K, Sherman SI, Somerset H, Sosa JA, Steward DL, Wartofsky L, Williams MD. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid. 2017 04; 27(4):481-483.
    View in: PubMed
    Score: 0.414
  8. Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? Cancer. 2017 02 01; 123(3):372-381.
    View in: PubMed
    Score: 0.404
  9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan; 26(1):1-133.
    View in: PubMed
    Score: 0.382
  10. Patel NU, McKinney K, Kreidler SM, Bieker TM, Russ P, Roberts K, Glueck DH, Albuja-Cruz M, Klopper J, Haugen BR. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. J Clin Ultrasound. 2016 Mar-Apr; 44(3):143-51.
    View in: PubMed
    Score: 0.375
  11. Pozdeyev N, Berlinberg A, Zhou Q, Wuensch K, Shibata H, Wood WM, Haugen BR. Targeting the NF-?B Pathway as a Combination Therapy for Advanced Thyroid Cancer. PLoS One. 2015; 10(8):e0134901.
    View in: PubMed
    Score: 0.372
  12. Klopper J, Kane M, Jimeno A, Sams S, French J, Pike L, Tompkins K, Haugen B. A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer. Thyroid. 2015 May; 25(5):563-4.
    View in: PubMed
    Score: 0.363
  13. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1436-44.
    View in: PubMed
    Score: 0.340
  14. Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014 Mar 19; 13:62.
    View in: PubMed
    Score: 0.338
  15. Haugen BR, Sherman SI. Evolving approaches to patients with advanced differentiated thyroid cancer. Endocr Rev. 2013 Jun; 34(3):439-55.
    View in: PubMed
    Score: 0.317
  16. Haugen BR. Radioiodine remnant ablation: current indications and dosing regimens. Endocr Pract. 2012 Jul-Aug; 18(4):604-10.
    View in: PubMed
    Score: 0.300
  17. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC, Klopper JP, Haugen BR. Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab. 2012 Jun; 97(6):E934-43.
    View in: PubMed
    Score: 0.295
  18. Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid. 2011 Sep; 21(9):941-4.
    View in: PubMed
    Score: 0.283
  19. Haugen BR, Duncan MW. Applications of proteomics to thyroid neoplasms: are we there yet? Thyroid. 2010 Oct; 20(10):1051-2.
    View in: PubMed
    Score: 0.266
  20. Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010 May 21; 9:117.
    View in: PubMed
    Score: 0.259
  21. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR. Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab. 2010 May; 95(5):2325-33.
    View in: PubMed
    Score: 0.255
  22. Haugen BR, Kane MA. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab. 2010 Mar; 95(3):987-93.
    View in: PubMed
    Score: 0.255
  23. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid. 2009 Aug; 19(8):825-35.
    View in: PubMed
    Score: 0.245
  24. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009 Jun; 94(6):2199-203.
    View in: PubMed
    Score: 0.239
  25. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008 Nov; 93(11):4331-41.
    View in: PubMed
    Score: 0.229
  26. Haugen BR, Cooper DS, Emerson CH, Luster M, Maciel RM, Biscolla RP, Mazzaferri EL, Medeiros-Neto G, Reiners C, Robbins RJ, Robinson BG, Schlumberger M, Yamashita S, Pacini F. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008 Jul; 18(7):687-94.
    View in: PubMed
    Score: 0.227
  27. Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthi U, Janssen J, Singh M, Bissonnette RP, Haugen BR. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res. 2008 Jan 15; 14(2):589-96.
    View in: PubMed
    Score: 0.220
  28. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug; 45(8):613-26.
    View in: PubMed
    Score: 0.199
  29. Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder M, Spitzweg C, Worden FP, Wirth L, Ho A. Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. Lancet Diabetes Endocrinol. 2025 06; 13(6):516-527.
    View in: PubMed
    Score: 0.183
  30. Barrio MJ, Pozdeyev N, McIntyre RC, Albuja-Cruz MB, Haugen BR, Raeburn CD. Long term outcomes after repeat lymph node dissections for persistent or recurrent differentiated thyroid cancer. Am J Surg. 2025 Jan; 239:116045.
    View in: PubMed
    Score: 0.176
  31. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004 Oct; 122(4):524-31.
    View in: PubMed
    Score: 0.175
  32. French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Sep 03; 30(17):3757-3767.
    View in: PubMed
    Score: 0.174
  33. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep; 4(3):175-80.
    View in: PubMed
    Score: 0.174
  34. Woodmansee WW, Haugen BR. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf). 2004 Aug; 61(2):163-73.
    View in: PubMed
    Score: 0.173
  35. Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab. 2004 Aug; 89(8):3665-7.
    View in: PubMed
    Score: 0.173
  36. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther. 2004 Aug; 3(8):1011-20.
    View in: PubMed
    Score: 0.173
  37. Barrio MJ, Pozdeyev N, Raeburn CD, McIntyre RC, Marshall CB, Haugen B, La Greca A. Pre-operative thyroglobulin measurement for thyroid cancer risk of recurrence and response to therapy. Am J Surg. 2024 Dec; 238:115818.
    View in: PubMed
    Score: 0.172
  38. Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC, Singer MC, Stack BC, Wirth LJ, Wong RJ, Randolph GW. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024 03 01; 150(3):265-272.
    View in: PubMed
    Score: 0.168
  39. Pozdeyev N, Dighe M, Barrio M, Raeburn C, Smith H, Fisher M, Chavan S, Rafaels N, Shortt JA, Lin M, Leu MG, Clark T, Marshall C, Haugen BR, Subramanian D, Crooks K, Gignoux C, Cohen T. Thyroid Cancer Polygenic Risk Score Improves Classification of Thyroid Nodules as Benign or Malignant. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):402-412.
    View in: PubMed
    Score: 0.167
  40. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab. 2004 Jan; 89(1):272-80.
    View in: PubMed
    Score: 0.166
  41. Chiosea S, Hodak SP, Yip L, Abraham D, Baldwin C, Baloch Z, Gulec SA, Hannoush ZC, Haugen BR, Joseph L, Kargi AY, Khanafshar E, Livhits MJ, McIver B, Patel K, Patel SG, Randolph GW, Shaha AR, Sharma J, Stathatos N, van Zante A, Carty SE, Nikiforov YE, Nikiforova MN. Molecular Profiling of 50 734 Bethesda III-VI Thyroid Nodules by ThyroSeq v3: Implications for Personalized Management. J Clin Endocrinol Metab. 2023 10 18; 108(11):2999-3008.
    View in: PubMed
    Score: 0.164
  42. Greca A, Grau L, Arbet J, Liao LM, Sosa JA, Haugen BR, Kitahara CM. Anthropometric, dietary, and lifestyle factors and risk of advanced thyroid cancer: The NIH-AARP diet and health cohort study. Clin Endocrinol (Oxf). 2023 12; 99(6):586-597.
    View in: PubMed
    Score: 0.163
  43. Sugawara M, Matsuzuka F, Fukata S, Kuma K, Moatamed F, Haugen BR. Excessive survivin expression in thyroid lymphomas. Hum Pathol. 2002 May; 33(5):524-7.
    View in: PubMed
    Score: 0.148
  44. Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours. Clin Endocrinol (Oxf). 2002 Mar; 56(3):281-90.
    View in: PubMed
    Score: 0.147
  45. Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 02; 32(2):153-163.
    View in: PubMed
    Score: 0.145
  46. Mehta V, Naraparaju A, Liao D, Davies L, Haugen BR, Kopp PA, Mandel SJ, Nikiforov YE, Ross DS, Shin JJ, Tuttle RM, Randolph GW. What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision. Thyroid. 2022 04; 32(4):421-428.
    View in: PubMed
    Score: 0.145
  47. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid. 2002 Jan; 12(1):37-43.
    View in: PubMed
    Score: 0.145
  48. Figge JJ, Gooding WE, Steward DL, Yip L, Sippel RS, Yang SP, Scheri RP, Sipos JA, Mandel SJ, Mayson SE, Burman KD, Folek JM, Haugen BR, Sosa JA, Parameswaran R, Tan WB, Nikiforov YE, Carty SE. Do Ultrasound Patterns and Clinical Parameters Inform the Probability of Thyroid Cancer Predicted by Molecular Testing in Nodules with Indeterminate Cytology? Thyroid. 2021 11; 31(11):1673-1682.
    View in: PubMed
    Score: 0.142
  49. Haugen BR, Lin EC. Isotope imaging for metastatic thyroid cancer. Endocrinol Metab Clin North Am. 2001 Jun; 30(2):469-92.
    View in: PubMed
    Score: 0.139
  50. Haugen BR. The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated. Thyroid. 2000 Nov; 10(11):971-3.
    View in: PubMed
    Score: 0.134
  51. Pozdeyev N, Erickson TA, Zhang L, Ellison K, Rivard CJ, Sams S, Hirsch FR, Haugen BR, French JD. Comprehensive Immune Profiling of Medullary Thyroid Cancer. Thyroid. 2020 09; 30(9):1263-1279.
    View in: PubMed
    Score: 0.129
  52. Haugen BR. Initial treatment of differentiated thyroid carcinoma. Rev Endocr Metab Disord. 2000 Apr; 1(3):139-45.
    View in: PubMed
    Score: 0.128
  53. Sawka AM, Gagliardi AR, Haymart MR, Sturgeon C, Bernet V, Hoff K, Angelos P, Brito JP, Haugen BR, Kim B, Kopp PA, Mandel SJ, Ross DS, Samuels M, Sarne D, Sinclair C, Jonklaas J. A Survey of American Thyroid Association Members Regarding the 2015 Adult Thyroid Nodule and Differentiated Thyroid Cancer Clinical Practice Guidelines. Thyroid. 2020 01; 30(1):25-33.
    View in: PubMed
    Score: 0.126
  54. Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 11 15; 25(22):6883-6884.
    View in: PubMed
    Score: 0.125
  55. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999 Nov; 84(11):3877-85.
    View in: PubMed
    Score: 0.125
  56. Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 05 15; 25(10):3141-3151.
    View in: PubMed
    Score: 0.119
  57. Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, Figge JJ, Mandel S, Haugen BR, Burman KD, Baloch ZW, Lloyd RV, Seethala RR, Gooding WE, Chiosea SI, Gomes-Lima C, Ferris RL, Folek JM, Khawaja RA, Kundra P, Loh KS, Marshall CB, Mayson S, McCoy KL, Nga ME, Ngiam KY, Nikiforova MN, Poehls JL, Ringel MD, Yang H, Yip L, Nikiforov YE. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study. JAMA Oncol. 2019 02 01; 5(2):204-212.
    View in: PubMed
    Score: 0.118
  58. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol. 1999 Jan-Feb; 16(1):34-41.
    View in: PubMed
    Score: 0.118
  59. Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S, Ferris RL, Haugen BR, Harrell RM, Haymart MR, McIver B, Mechanick JI, Monteiro E, Morris JC, Morris LGT, Odell M, Scharpf J, Shaha A, Shin JJ, Shonka DC, Thompson GB, Tuttle RM, Urken ML, Wiseman SM, Wong RJ, Randolph G. American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck. 2019 04; 41(4):843-856.
    View in: PubMed
    Score: 0.117
  60. McIver B, Freeman J, Shah JP, Shaha AR, Haugen B, Cohen E, Witterick IJ, Randolph GW. Summary of the Third World Congress on Thyroid Cancer. Thyroid. 2018 11; 28(11):1401-1405.
    View in: PubMed
    Score: 0.116
  61. Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 06; 28(6):739-747.
    View in: PubMed
    Score: 0.113
  62. Giordano TJ, Haugen BR, Sherman SI, Shah MH, Caoili EM, Koenig RJ. Pioglitazone Therapy of PAX8-PPAR? Fusion Protein Thyroid Carcinoma. J Clin Endocrinol Metab. 2018 04 01; 103(4):1277-1281.
    View in: PubMed
    Score: 0.112
  63. Haugen BR, Nawaz S, Markham N, Hashizumi T, Shroyer AL, Werness B, Shroyer KR. Telomerase activity in benign and malignant thyroid tumors. Thyroid. 1997 Jun; 7(3):337-42.
    View in: PubMed
    Score: 0.105
  64. Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why? Thyroid. 2017 06; 27(6):751-756.
    View in: PubMed
    Score: 0.105
  65. French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol. 2017 06; 5(6):469-481.
    View in: PubMed
    Score: 0.101
  66. Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC, Haugen BR, French JD. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer. J Clin Endocrinol Metab. 2016 07; 101(7):2863-73.
    View in: PubMed
    Score: 0.097
  67. McLeod DS, Jonklaas J, Brierley JD, Ain KB, Cooper DS, Fein HG, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Xing M, Litofsky DR, Maxon HR, Sherman SI. Reassessing the NTCTCS Staging Systems for Differentiated Thyroid Cancer, Including Age at Diagnosis. Thyroid. 2015 Oct; 25(10):1097-105.
    View in: PubMed
    Score: 0.093
  68. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab. 2015 Sep; 100(9):3270-9.
    View in: PubMed
    Score: 0.093
  69. Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun; 6(2-3):87-99.
    View in: PubMed
    Score: 0.091
  70. Severson JJ, Serracino HS, Mateescu V, Raeburn CD, McIntyre RC, Sams SB, Haugen BR, French JD. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer. Cancer Immunol Res. 2015 Jun; 3(6):620-30.
    View in: PubMed
    Score: 0.090
  71. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb; 100(2):E243-52.
    View in: PubMed
    Score: 0.089
  72. Olson AC, Haugen BR, Walter J, Kwak JJ, Bagrosky BM, Koo PJ. SPECT/CT and I131 therapy of brain metastases from follicular variant papillary thyroid carcinoma (FVPTC). J Clin Endocrinol Metab. 2014 Oct; 99(10):3511-2.
    View in: PubMed
    Score: 0.087
  73. Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul; 99(7):E1368-75.
    View in: PubMed
    Score: 0.085
  74. Haugen BR, Nawaz S, Cohn A, Shroyer K, Bunn PA, Liechty DR, Ridgway EC. Secondary malignancy of the thyroid gland: a case report and review of the literature. Thyroid. 1994; 4(3):297-300.
    View in: PubMed
    Score: 0.083
  75. Sosa JA, Elisei R, Jarzab B, Balkissoon J, Lu SP, Bal C, Marur S, Gramza A, Yosef RB, Gitlitz B, Haugen BR, Ondrey F, Lu C, Karandikar SM, Khuri F, Licitra L, Remick SC. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014 Feb; 24(2):232-40.
    View in: PubMed
    Score: 0.081
  76. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013 Mar 23; 381(9871):1058-69.
    View in: PubMed
    Score: 0.079
  77. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 01; 18(13):3580-91.
    View in: PubMed
    Score: 0.074
  78. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012 Jun; 97(6):E878-87.
    View in: PubMed
    Score: 0.074
  79. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010 Dec; 20(12):1423-4.
    View in: PubMed
    Score: 0.067
  80. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov; 19(11):1167-214.
    View in: PubMed
    Score: 0.062
  81. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2009 Nov; 94(11):4171-9.
    View in: PubMed
    Score: 0.062
  82. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009 Oct; 19(10):1043-8.
    View in: PubMed
    Score: 0.062
  83. Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR, Haugen BR, Duncan MW. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 2008 Mar 01; 68(5):1572-80.
    View in: PubMed
    Score: 0.056
  84. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006 Dec; 16(12):1229-42.
    View in: PubMed
    Score: 0.051
  85. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP, Smallridge RC. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006 Apr 13; 25(16):2304-17.
    View in: PubMed
    Score: 0.049
  86. H?nscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006 Apr; 47(4):648-54.
    View in: PubMed
    Score: 0.049
  87. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006 Feb; 16(2):109-42.
    View in: PubMed
    Score: 0.048
  88. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006 Mar; 91(3):878-84.
    View in: PubMed
    Score: 0.048
  89. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006 Mar; 91(3):926-32.
    View in: PubMed
    Score: 0.048
  90. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Apr; 88(4):1433-41.
    View in: PubMed
    Score: 0.039
  91. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR. Outcome after treatment of high-risk papillary and non-H?rthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998 Oct 15; 129(8):622-7.
    View in: PubMed
    Score: 0.029
  92. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998 Sep 01; 83(5):1012-21.
    View in: PubMed
    Score: 0.029
  93. McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley JD, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014 Jan; 24(1):35-42.
    View in: PubMed
    Score: 0.020
  94. Mambo E, Chatterjee A, Xing M, Tallini G, Haugen BR, Yeung SC, Sukumar S, Sidransky D. Tumor-specific changes in mtDNA content in human cancer. Int J Cancer. 2005 Oct 10; 116(6):920-4.
    View in: PubMed
    Score: 0.012
  95. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid. 1998 Sep; 8(9):737-44.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)